Zai Lab Beheer

Beheer criteriumcontroles 3/4

De CEO Zai Lab is Samantha Du, benoemd in Jan2014, heeft een ambtstermijn van 10.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 12.04M, bestaande uit 7.2% salaris en 92.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.01% van de aandelen van het bedrijf, ter waarde MX$ 574.97M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.1 jaar en 6.2 jaar.

Belangrijke informatie

Samantha Du

Algemeen directeur

US$12.0m

Totale compensatie

Percentage CEO-salaris	7.2%
Dienstverband CEO	10.8yrs
Eigendom CEO	1.0%
Management gemiddelde ambtstermijn	2.1yrs
Gemiddelde ambtstermijn bestuur	6.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Samantha Du's beloning veranderd ten opzichte van Zai Lab's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$271m
Jun 30 2024	n/a	n/a	-US$298m
Mar 31 2024	n/a	n/a	-US$339m
Dec 31 2023	US$12m	US$869k	-US$335m
Sep 30 2023	n/a	n/a	-US$301m
Jun 30 2023	n/a	n/a	-US$393m
Mar 31 2023	n/a	n/a	-US$410m
Dec 31 2022	US$20m	US$830k	-US$443m
Sep 30 2022	n/a	n/a	-US$593m
Jun 30 2022	n/a	n/a	-US$529m
Mar 31 2022	n/a	n/a	-US$554m
Dec 31 2021	US$15m	US$774k	-US$704m
Sep 30 2021	n/a	n/a	-US$569m
Jun 30 2021	n/a	n/a	-US$537m
Mar 31 2021	n/a	n/a	-US$454m
Dec 31 2020	US$9m	US$689k	-US$269m
Sep 30 2020	n/a	n/a	-US$239m
Jun 30 2020	n/a	n/a	-US$240m
Mar 31 2020	n/a	n/a	-US$201m
Dec 31 2019	US$9m	US$656k	-US$195m
Sep 30 2019	n/a	n/a	-US$212m
Jun 30 2019	n/a	n/a	-US$181m
Mar 31 2019	n/a	n/a	-US$160m
Dec 31 2018	US$6m	US$638k	-US$139m

Compensatie versus markt: De totale vergoeding ($USD 12.04M ) Samantha } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de MX markt ($USD 1.26M ).

Compensatie versus inkomsten: De vergoeding van Samantha is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Samantha Du (58 yo)

10.8yrs

Tenure

US$12,042,285

Compensatie

Dr. Ying Du, Ph D., also known as Samantha, serves as Founding Managing Director at Quan Capital. She served as Venture Partner at Sequoia Capital China.Dr. Du serves as an adjunct professor at Fudan Univ...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ying Du	Founder	10.8yrs	US$12.04m	1.01% MX$ 575.0m
Joshua L. Smiley	President & COO	2.3yrs	US$5.55m	0.044% MX$ 25.0m
Rafael G. Amado	President and Head of Global Research & Development	1.8yrs	US$4.87m	0.021% MX$ 11.8m
Yajing Chen	Chief Financial Officer	1.3yrs	US$2.01m	0.016% MX$ 9.0m
Peter Huang	Chief Scientific Officer	2yrs	geen gegevens	geen gegevens
Christine Chiou	Senior VP & Head of Investor Relations	1.5yrs	geen gegevens	geen gegevens
Frazor Titus Edmondson	Chief Legal Officer & Joint Corporate Secretary	4.3yrs	US$5.63m	0.029% MX$ 16.7m
Ning Xu	Executive VP & Head of Clinical Operations	10.8yrs	geen gegevens	geen gegevens
Jonathan J. Wang	Chief Business Officer	10.8yrs	geen gegevens	geen gegevens
James Yan	Chief Operating Officer of R&D	9.8yrs	geen gegevens	geen gegevens
Tong Zhu	Chief Commercial Officer of Greater China	less than a year	geen gegevens	geen gegevens
Robert Brown	Chief Medical Officer of Oncology	1.2yrs	geen gegevens	geen gegevens

2.1yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ZLAB N wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ying Du	Founder	10.8yrs	US$12.04m	1.01% MX$ 575.0m
Leon Moulder	Independent Director	4.8yrs	US$574.35k	0.041% MX$ 23.4m
Peter Karl Wirth	Independent Director	7.8yrs	US$576.15k	0.37% MX$ 209.2m
John David Diekman	Lead Independent Director	7.8yrs	US$608.44k	0.069% MX$ 39.1m
Scott William Morrison	Independent Director	3.1yrs	US$570.77k	0.053% MX$ 30.4m
William David Lis	Independent Director	6.1yrs	US$567.03k	0.054% MX$ 30.7m
Michel Vounatsos	Independent Director	1.8yrs	US$821.25k	0.019% MX$ 10.6m
Richard Brian Gaynor	Independent Director	3yrs	US$564.98k	0.026% MX$ 14.6m
Kai-Xian Chen	Independent Director	6.3yrs	US$557.48k	0.048% MX$ 27.3m
Wing-Yu Leung	Independent Director	10.8yrs	geen gegevens	geen gegevens

6.2yrs

Gemiddelde duur

66.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ZLAB N wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.2 jaar).

Zai Lab Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Zai Lab Limited Announces Executive Changes, Effective June 30, 2024

Zai Lab Limited, Annual General Meeting, Jun 18, 2024

Zai Lab Limited Announces Chief Financial Officer Changes, Effective July 7, 2023

Zai Lab Limited Appoints Michel Vounatsos to the Board of Directors

Zai Lab Limited Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

Independent Director recently sold Mex$5.5m worth of stock

Recent updates

Zai Lab Limited has completed a Follow-on Equity Offering in the amount of $199.999994 million.

Zai Lab Limited has filed a Follow-on Equity Offering in the amount of $200 million.

Third quarter 2024 earnings released: US$0.42 loss per share (vs US$0.71 loss in 3Q 2023)

Zai Lab Limited and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

Zai Lab Limited Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China

Zai Lab Limited Presents Data from the Ongoing Global Phase 1A/1B Study of ZL-1310

Zai Lab Limited to Report Q3, 2024 Results on Nov 12, 2024

Zai Lab Limited to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024

Zai Lab Limited to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024

Zai Lab and argenx Announces Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

Zai Lab Limited to Report Q2, 2024 Results on Aug 06, 2024

Zai Lab Limited Announces Executive Changes, Effective June 30, 2024

Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

Zai Lab Limited Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA

First quarter 2024 earnings released: US$0.55 loss per share (vs US$0.51 loss in 1Q 2023)

Forecast to breakeven in 2026

Zai Lab Limited to Report Q1, 2024 Results on May 08, 2024

Zai Lab Limited, Annual General Meeting, Jun 18, 2024

Zai Lab Partner Novocure Announces Metis Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

Zai Lab Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Zai Lab Limited to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

Zai Lab Limited to Report Fiscal Year 2023 Results on Feb 27, 2024

Zai Lab Announces the New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC

Zai Lab Limited Announces the First Listing of VYVGART(R) (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List

Zai Lab Limited to Report Q3, 2023 Results on Nov 07, 2023

Zai Lab Limited Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with Ntrk-Positive Tki-Pretreated Advanced Solid Tumors in China

Zai Lab Limited to Report Q2, 2023 Results on Aug 07, 2023

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis

Zai Lab Limited Announces Chief Financial Officer Changes, Effective July 7, 2023

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Zai Lab Limited to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting

Zai Lab Limited Announces China’s National Medical Products Administration Grants Priority Review to Repotrectinib

First quarter 2023 earnings released: US$0.51 loss per share (vs US$0.86 loss in 1Q 2022)

Zai Lab Limited to Report Fiscal Year 2022 Results on Mar 01, 2023

Zai Lab Limited Announces New Drug Application for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s National Medical Products Administration

Zai Lab Limited Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List

Zai Lab Limited Appoints Michel Vounatsos to the Board of Directors

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Zai Lab Limited Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

Independent Director recently sold Mex$5.5m worth of stock

Zai Lab Limited Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary

Independent Director recently sold Mex$5.5m worth of stock

Third quarter 2022 earnings released: US$1.68 loss per share (vs US$1.01 loss in 3Q 2021)

Zai Lab Limited Announces the Appointment of Peter Huang as Chief Scientific Officer

Zai Lab Limited to Report Q3, 2022 Results on Nov 09, 2022

Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting

Second quarter 2022 earnings released: US$1.44 loss per share (vs US$1.76 loss in 2Q 2021)

Zai Lab Limited Appoints Joshua Smiley as Chief Operating Officer

Zai Lab Limited to Report Q2, 2022 Results on Aug 09, 2022

China’s National Medical Products Administration Accepts Biologics License Application of Zai Lab Limited

Zai Lab Limited Announces Breakthrough Therapy Designations Granted for Repotrectinib in China

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

First quarter 2022 earnings released: US$0.86 loss per share (vs US$2.64 loss in 1Q 2021)

Zai Lab Limited, Annual General Meeting, Jun 22, 2022

Zai Lab Limited to Report Q1, 2022 Results on May 10, 2022

No longer forecast to breakeven

Zai Lab Limited Announces Resignation of Tao Fu, Chief Strategy Officer

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Zai Lab Limited to Report Fiscal Year 2021 Results on Mar 02, 2022

Zai Lab Limited to Report Fiscal Year 2021 Results on Mar 01, 2022

Forecast to breakeven in 2024

Zai Lab Limited Announces Treatment of First Patient in Greater China in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer

Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA

Zai Lab Limited Announces China NMPA's Approval for NUZYRA® as A Category 1 Innovative Drug for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Zai Lab Announces Inclusion of Zejula® (Niraparib) in China's National Reimbursement Drug List for First-Line Ovarian Cancer